

Pharmacological and Toxicity Profiles of Diverse Paclitaxel Preparations with Detoxifying Nanoformulations

Sida Zhang

*Int'l Division, Shanghai Southwest Weiyu Secondary School, Shanghai, China
sterlingzhangsida@outlook.com*

Abstract. Paclitaxel, a first-line chemotherapeutic agent widely used to treat a broad spectrum of solid malignancies, exerts potent antitumor activity by disrupting microtubule dynamics and arresting mitotic division of proliferating cancer cells. Its earliest marketed formulation utilizes Cremophor EL as a solubilizing excipient to overcome the poor aqueous solubility of paclitaxel. However, Cremophor EL is known to trigger severe adverse reactions, including acute hypersensitivity, peripheral neuropathy and leukopenia, greatly limiting the maximum safe administrable dose in clinical practice. To tackle these drawbacks, a variety of paclitaxel nanocarrier systems have been engineered to eliminate Cremophor EL. Such nanoformulations promote selective intratumoral drug accumulation relying on the enhanced permeability and retention (EPR) effect, effectively lowering excipient-related systemic toxicity. Although these strategies achieve encouraging therapeutic efficacy in preclinical animal investigations, the promising preclinical benefits cannot be fully recapitulated in subsequent clinical trials. Current paclitaxel nanoformulations still confront multiple unresolved hurdles, such as high manufacturing expenditure, intrinsic cytotoxicity of nanocarriers, latent chronic toxic risks and inadequate passive targeting efficiency. This article delineates paclitaxel's pharmacological mechanism, toxic features of conventional preparations, nanotechnology-enabled detoxification tactics, safety profiles, as well as persistent obstacles hindering further clinical translation.

Keywords: paclitaxel, Cremophor EL, nanomedicine, toxicity of drugs and of their side effects, tumor targeting

1. Introduction

With the discovery and confirmation of paclitaxel's anti tumor properties, it has been regarded as one of the main chemotherapy agents applicable to breast cancer, lung cancer or ovarian cancer. Older forms of paclitaxel injection made use of substantial quantities of Cremophor EL and of anhydrous ethanol to overcome poor solubility in water. Extended clinical study now demonstrates definite safety problems with that solvent combination. Steroids and antihistamines are necessary for every infusion session. Such extra precautions make planning difficult, and long-term steroid therapy adds physical stress to the patient.

Nonpharmaceutical technology has developed sufficiently to yield multiple Cremophor-free modified paclitaxel formulations used clinically today. Albumin-bound paclitaxel is currently the

nanoformulation most widely applied in medical settings. With liposomal paclitaxel the drug resides in phospholipid vesicles — no harmful solvent reaches the surrounding tissue directly. Polymer nanocarriers are still at an early stage of study; their scaffolds are adaptable, enabling precise chemical targeting if desired. Each of these formulations shows a unique profile with regard to metabolism, tissue uptake and side effects. Retrospective clinical reports, meta-analyses and recent animal toxicology data have been assembled to compare toxicity among such preparations.

Looking at present-day publications, it is clear that most reviews mention only one particular nano paclitaxel formulation. Very few attempt to track fully the relevant research: basic drug properties, traditional toxicity patterns of non-modified drugs, means of toxicity reduction with new variants, comparative safety of several drug forms, and obstacles still facing development. This article brings together past pharmacological studies, major clinical samples and current nanopharmaceutical literature. It may be of value in helping students — or investigators — plan a review or thesis. However, even existing reviews can sometimes draw different conclusions when ranking the safety of these nanoformulations. Differences in trial inclusion criteria and dosage schemes can lead to conflicting safety conclusions across the meta-analyses.

2. Basic pharmacology and toxicity mechanisms of paclitaxel

2.1. Basic antitumor mechanism of paclitaxel

Paclitaxel is to be regarded as a chemotherapeutic agent that targets microtubules. The molecular basis of its anticancer activity has been well studied — both in pre clinical contexts and in published reviews. Among the cytoskeletal elements, microtubules are built up of two subunits known as α tubulin and β tubulin. At mitosis they help to assemble spindles, which are essential for the correct positioning and separation of chromosomes. To put it briefly, the interplay of polymerization and depolymerization of microtubules is a basic prerequisite for viable cell division.

Paclitaxel acts selectively by binding to certain sites of β tubulin. It favors assembly of individual tubulin monomers. But will not break it into microtubules and suppresses depolymerization of such structures. Thus microtubules come to be abnormally stabilized and lose their dynamic regulatory role.

At the metaphase of mitosis (in tumor cells) spindles no longer direct the orderly division of chromosomes. The cell cycle is blocked at or near the G₂/M boundary. Such prolonged cell cycle arrest starts a sequence of apoptotic signals in the tumor cell, which may stop growth or lead to cancer cell death [1].

The pharmacological sequence in question is central both to paclitaxel's clinically useful anticancer properties and to its natural toxic potential. Changing the delivery system or reformulating the dosage form does not prevent paclitaxel from indiscriminately damaging microtubules throughout fast-growing human cells. Highly proliferative cell types — such as hematopoietic cells of the bone marrow or of the periphery, Schwann nerve elements, or epithelial cells lining the gut — tend to be vulnerable to such damage by paclitaxel. Unfortunately, attempts at formulation-based modification do not wholly neutralize the drug's built-in cytotoxicity. This intrinsic cytotoxicity sets an upper limit for how much safety improvement we can achieve purely through carrier redesign.

2.2. Core cause of adverse effects for conventional formulations: deficiencies of cremophor EL excipient

Paclitaxel is known to have very poor solubility in water. Simple aqueous preparations are not adequate for achieving clinically useful drug levels. Among the first generation commercial paclitaxel injections, cremophor EL—that is, polyethoxylated castor oil—was used together with anhydrous ethanol as a co solubilizing agent to dissolve paclitaxel for intravenous (IV) administration.

Researchers had already observed severe adverse effects brought by conventional paclitaxel injections. Later, more work confirmed that Cremophor-EL Its toxic features coincide or compound those of paclitaxel-induced cytotoxicity, and this worsens a wide range of adverse outcomes for individual patients [2].

When cremophor EL is introduced to systemic circulation it begins to self-assemble as micelles capable of many toxic effects. Among the first consequences are activation of the human complement system and prompt type hypersensitivity phenomena. The clinical picture varies greatly: in mild forms there is pruritus or erythema (or urticaria); for severe cases bronchospasm may be one of the symptoms, dyspnea and sharp hypotension. Under extreme circumstances, fatal anaphylactic shock may arise. Even apart from hypersensitivity, massive amounts of circulating micellar complexes disturb equilibrium of binding between plasma constituents and paclitaxel, with ensuing changes in transport of the drug and in its tissue localization — both harmful to nerves and to kidneys. Anhydrous ethanol present in the formulation aggravates neural dysfunction and worsens symptoms (such as limb numbness or hypoesthesia) of peripheral neuropathy. Existing domestic reviews detail the toxicity of this excipient and offer pointers for similar investigations conducted locally or at home [3].

2.3. Molecular pathways mediating formulation-induced toxicity

Among the findings of Klein's research group is a classification of paclitaxel related toxicities into two mechanistic types: direct tissue injury due to an excipient, or secondary toxicity caused by faulty drug transport. Each of these mechanisms works somewhat separately but may overlap, and both seem to help explain a wide range of harmful clinical outcomes for individual patients [4].

The initial pathway refers specifically to direct tissue injury from cremophor EL. Cremophor EL promotes secretion of numerous pro inflammatory cytokines by vascular endothelial cells and causes localized vascular inflammation. Myelin sheaths of peripheral nerves become damaged and nerve fibers are impaired. Micellar complexes—when accumulating progressively—may overload the liver or kidney with oxidative stress, a factor that favors long-term chronic injury of those organs.

The second pathway is one of secondary toxicity caused by solvent-related modification of drug distribution. Micelles generated by cremophor EL seem to disturb paclitaxel trafficking and to change the way it reaches various tissues. Much of the drug given enters normal organs—peripheral nerves or bone marrow—rather than tumors, with little penetration into malignant sites. It is not surprising that anticancer effectiveness suffers greatly here, while systemic toxicity rises markedly. From a clinical standpoint, myelosuppression and long-term neuropathy are frequent complications. It should also be noted that some in-vitro observations of Cremophor-EL toxicity cannot be fully reproduced in all human clinical samples. As Figure 1 shows, Cremophor-EL triggers intracellular oxidative stress and activates downstream signaling pathways [5].




Figure 1. Schematic of cellular toxicity induced by Cremophor-EL. Oxidative stress, p38 MAPK activation, IL-8 mRNA stabilization and upregulated IL-8 protein synthesis upon Cremophor-EL exposure [5]

3. Major clinical drawbacks of conventional paclitaxel injection

3.1. High occurrence of severe hypersensitivity reactions

Hypersensitivity reactions triggered by cremophor EL represent the most striking clinical complication of conventional paclitaxel formulations. Large-sample clinical research carried out by Weiss and coworkers demonstrated that without premedication, more than 9 % of patients receiving direct paclitaxel infusion develop severe hypersensitivity reactions. In real-world hospitals, the actual incidence may also shift according to infusion speed and patient physical status. In worst-case situations, life-threatening anaphylactic shock may occur [6].

To mitigate hypersensitivity risks, pretreatment with glucocorticoids and antihistamines is mandatory prior to drug infusion. Understandably, such premedication regimens extend the duration of each chemotherapy session. Worse still, glucocorticoids themselves bring additional side-effects including blood-glucose fluctuation, gastrointestinal irritation and immunosuppression. Patients endure greater physiological burden, and clinical workflows become more cumbersome. It is worth noting that these hypersensitivity hazards originate entirely from the cremophor EL excipient rather than paclitaxel active substance.

3.2. Lack of tumor-targeting capacity and extensive drug retention in normal tissues

From animal biodistribution studies it is evident that very large micelles—produced by cremophor EL—are unlikely to traverse vascular endothelial spaces of solid tumors in the blood. Also, such micelles seem to block access of paclitaxel to albumin-type binding sites on malignant cells, which reduces the amount of drug taken up by the tumor. Once in systemic circulation, a significant portion of the administered drug deposits and present in normal tissues—skin, peripheral nerves or

bone marrow—while their concentration inside tumors is far from ideal therapeutically. Such dual behavior tends to reduce the effectiveness of anticancer treatment and to worsen systemic side effects. Retention of too much drug by nontumorous tissues is one major factor underlying the frequent clinical occurrence of myelosuppression and neurotoxicity [7], as shown in Figure 2 [8].




Figure 2. Lack of tumor-targeting capacity and high drug retention in normal tissues. (a) Dorsal and ventral fluorescence images of mice at serial time points. (b) Normalized fluorescence in tumor and major organs. (c) Time profile of tumor-to-background ratio (TBR)

3.3. Non-linear pharmacokinetics and progressive toxic accumulation

Standard paclitaxel formulations are known to show strong nonlinear pharmacokinetic characteristics tied closely to cremophor EL. Micelles formed by cremophor EL seem to compete with hepatic transporters—thus reducing the liver's capacity to clear paclitaxel. It is counterintuitive that increased dose yields slower elimination of the drug. With repeated administration, drug buildup within the body develops progressively. As the chemotherapy regimen proceeds, both myelosuppression and neuropathy (often irreversible) become increasingly dangerous [9].

A number of statistical studies—some involving tens of thousands of clinical adverse event records—have established that multi-cycle chemotherapy based on regular paclitaxel still has high

rates of both neutropenia and peripheral neuropathy. Toxic effects due to drug accumulation define an upper bound for dose delivery and, to a certain degree, limit the full attainment of therapeutic goals.

4. Toxicity-reducing mechanisms and research progress of novel nano-paclitaxel formulations

Among the various nano-based drug delivery systems for paclitaxel there is general agreement regarding the design philosophy: remove hypersensitivity-inducing cremophor EL from formulations, and use nanoparticle dimensions as well as receptor binding and the enhanced permeability and retention (EPR) property of solid tumors to help localize drug at tumor sites. Such approaches essentially remove the possibility of hypersensitivity due to excipient-related risks may be curtailed at the same time that drug exposure of healthy tissues is lessened — a combination useful for reducing toxicity and improving therapy. Several nano-based preparations are known now, some (albumin-bound or liposomal) having passed into actual clinical use; polymeric micelles and PLGA nanoparticles remain under study in laboratories, with great room for improvement before they reach the clinic.

4.1. Albumin-bound paclitaxel

Albumin-bound paclitaxel employs human-derived albumin as a natural drug-carrier and is produced—by means of high pressure homogenization—as nanoparticles of roughly 130 nm size. Cremophor EL and ethanol at high concentrations no longer figure in its formula, removing the allergic risks brought by these traditional solubilizing agents. Among nano paclitaxel preparations, this one has been—up to now—the most frequently used in standard clinical practice worldwide.

Gradishar's research group has now finished work on a phase III trial involving breast cancer patients, with direct comparison of the efficacy and safety of albumin bound paclitaxel against conventional solvent based paclitaxel. From their findings it appears that albumin bound paclitaxel calls for no steroid pre-medication before infusion; severe hypersensitivity events were extremely rare for albumin-bound paclitaxel compared with solvent-based paclitaxel, which usually requires pre-treatment to avoid allergic reactions. With equivalent doses considered, it brings about better tumor responses and more reliable anticancer action [10].

Both in vitro studies and animal models confirm the existence of two tumor enrichment mechanisms. Nanoparticles utilize glycoprotein 60 (gp60) receptors—expressed on vascular endothelial cells—to carry out trans endothelial transport across vessel walls. At the same time, secreted protein acidic and rich in cysteine (SPARC) protein—common in the tumor microenvironment—binds to albumin-based vehicles, which leads to an increase in local drug levels inside the tumor and to a decrease in bone marrow or nerve-associated drug uptake (hence to lessened toxicity) [11]. Nevertheless, several real-world retrospective cohorts did not observe equally prominent reduction in peripheral neuropathy for albumin-bound paclitaxel compared with expectations from phase-III trials.

4.2. Liposomal paclitaxel

Liposomal paclitaxel is generally composed of phospholipids and cholesterol, with phospholipid bilayers serving to enclose individual paclitaxel molecules. Such phospholipid-based substances have good biocompatibility. Encapsulation of drugs in vesicles keeps free paclitaxel away from blood vessels and helps avoid vascular irritation. Liposomal nanoparticles do not provoke activation

of complement cascades, hypersensitivity risks seems to be substantially decreased. With prolonged circulation in mind, liposomes may be designed to stay longer in the bloodstream and—without active targeting—to concentrate at tumor sites by means of the EPR effect [12]. A number of domestic studies now analyze in detail the methods of preparation, the behavior in vivo and the safety of liposomal paclitaxel, giving guidance that is useful to local researchers [13].

Despite everything stated above, liposomal paclitaxel depends only partially upon active targeting for drug accumulation in the tumor. Some of the injected liposomal material is trapped by the hepatosplenic reticuloendothelial system—hence limited drug presence in liver or spleen. Toxic effects (hematological or neurological) of paclitaxel itself still occur.

4.3. Polymeric micelles and PLGA nanoparticles

Polymeric micelles and PLGA nanoparticles are typically constructed from biodegradable polymers such as PLGA or polyethylene glycol (PEG) block copolymers, which self-assemble into nanoscale drug delivery systems. Most candidates have only been tested at cellular or animal levels and are not widely used in clinics [14].

These polymeric carriers have distinct strengths: adjustable particle sizes and the capability to attach targeting ligands onto carrier surfaces for active targeting, offering versatile formulation strategies. Animal toxicology studies demonstrate that paclitaxel polymeric micelles cause less liver, kidney and peripheral nerve damage than conventional solvent-based formulations. Without extra modification, this formulation enables more tumor-selective drug accumulation and reduced toxicity [15].

Nevertheless, multiple challenges including large-scale production, quality management and in vivo degradation control remain unsolved. Substantial development work is still required before these formulations can advance to clinical trials.

4.4. General overview of nano-paclitaxel formulations

Each of the various nano paclitaxel formulations is distinct in terms of its carrier substances, of its manufacturing process, of its targeting mode and of its clinical development stage. Albumin-bound paclitaxel has known methods of preparation and has been used widely in clinical practice. Liposomal paclitaxel has gone through clinical testing and now begins to see expanded therapeutic use. Polymeric micelles and PLGA nanoparticles are still largely under study pre-clinically. Though active targeting modification seems promising, such approaches have not yet been fully industrialized or documented clinically.

As a group, nano paclitaxel formulations eliminate hypersensitivity-inducing excipients and bring about fewer excipient-related severe hypersensitivity events. With regard to EPR effect or receptor-based mechanisms, they help elevate local tumor drug levels and keep normal tissue exposure to drug minimal. It is important not to assume that nano carriers fully neutralize excipient toxicity — paclitaxel itself remains cytotoxic. Individual nano formulations vary greatly in their technical complexity, in cost of manufacture and in targeting capacity. Trade-offs of this sort and optimizations dictated by clinical realities may help define future paclitaxel delivery systems.

5. Comparative toxic-safety profiles of different paclitaxel formulations

Among the three principal research methods—meta analyses of several multi center randomized controlled trials, retrospective clinical cohort studies of real world usage, and standardized long term

in vivo animal toxicology tests—there is now a systematic attempt to evaluate, with regard to safety, the performance of each of the four formulations (solvent based, albumin bound, liposomal, or polymeric micelle) of paclitaxel.

Published meta-analyses integrating more than twenty randomized controlled trials mainly compared hypersensitivity, neutropenia and peripheral neuropathy between solvent-based paclitaxel and albumin-bound paclitaxel. Clinical evidence for liposomal and polymeric-micelle paclitaxel is relatively limited from randomized trials. As a rule, albumin-bound paclitaxel causes the least hypersensitivity (of all four forms) , then comes liposomal paclitaxel, whereas the standard Cremophor EL type is most toxic overall.

Among all tested formulations hematological adverse events remained a possibility, but nano based ones gave rise to far fewer cases of severe myelosuppression. A systematic review and meta-analysis of randomized controlled trials has summarized adverse-event profiles across paclitaxel formulations [16]. Multiple independent pre-clinical animal studies can quantitatively assess organ-associated drug accumulation, peripheral-nerve myelin damage, and bone-marrow suppression. Collective animal-derived evidence partially supports the toxicity-reducing benefits of nanocarrier-modified paclitaxel [17]. Comparative domestic/overseas studies of this sort may help to frame academic arguments.

6. Existing practical limitations of toxicity-attenuated nano-paclitaxel preparations

Even when nanocarriers largely prevent the bad effects of Cremophor EL (as an excipient), the translational gap between promising pre-clinical animal outcomes and real-world human therapeutic responses remains considerable. Many encouraging efficacy and safety observations obtained from laboratory animal models cannot be fully replicated in heterogeneous patient populations. Three basic bottlenecks—of clinical or therapeutic nature—continue to limit wide application of nano paclitaxel preparations.

6.1. High industrial production costs

Production of albumin-bound paclitaxel calls for high-pressure homogenization and aseptic lyophilization steps. Larger-scale liposome preparations need phospholipid raw materials of top-grade purity and aseptic filling arrangements. Polymeric nanocarriers depend on costly polymer feedstock per unit. Both complex manufacturing and exacting quality controls lead to very high prices for nano paclitaxel drugs — an economic hardship for individual patients and a barrier to use in basic health care [18]. High costs also create equity barriers, limiting access to these nanodrugs in resource-limited medical settings.

6.2. Persistent intrinsic cumulative toxicity of paclitaxel

Paclitaxel by its own nature causes damage to rapidly dividing somatic cells—without regard for excipients or carriers. Long term clinical observations have indicated that certain peripheral neuropathies or cumulative blood-related toxicities may persist even after many cycles of therapy, whether one uses albumin-bound or liposomal paclitaxel. Nanomedicines do not wholly remove the high-grade adverse effects resulting from paclitaxel but only lower their frequency [19], as illustrated by Figure 3 [20].




Figure 3. Taxane-induced peripheral neuropathy: damage to dorsal root ganglion, Schwann cells and myelin sheath, and pain signaling pathway from peripheral nerve to brain [20]

6.3. Deficient precision of passive targeting

Clinically approved nano paclitaxel preparations mostly rely on the EPR effect for passive tumor accumulation; albumin-bound paclitaxel additionally benefits from receptor-mediated endothelial transport. There is marked inter individual variation in vascular permeability for different patient tumors. A dense tumor stroma prevents nanoparticle access to the deeper parenchymal regions of the tumor. In addition, nanocarriers tend to be non specifically sequestered by the reticuloendothelial system of the liver or spleen — an unwanted source of drug leakage. With regard to targeting efficiency current results are not wholly satisfactory, and ligand-based active targeting seems a useful way forward.

6.4. General challenges in this field

Three universal obstacles—unaffordable manufacturing costs, non trivial toxicity after treatment, and poor targeting—were listed by reviews in authoritative journals as barriers to nano paclitaxel translation [21]. Among domestic researchers there has been a joint attempt to evaluate both the pharmaceutical situation and the medical facts, with proposals of practical remedies such as surface modification (for active targeting), low cost biodegradable substances, and co delivery methods to mitigate chemotherapy toxicity.

7. Conclusion

Replacing Cremophor EL with nanoscale carriers—albumin-bound particles, liposomes, and polymeric nanoparticles—has markedly reduced excipient-driven hypersensitivity and improved tumor selectivity, an advantage supported across meta-analyses, cohort studies, and preclinical toxicology. Albumin-bound paclitaxel has advanced furthest into clinical practice. This detoxification, however, remains incomplete: paclitaxel's intrinsic cytotoxicity still drives peripheral neuropathy and hematological toxicity, manufacturing costs stay high, and passive targeting through the EPR effect varies substantially between tumors and individual patients. These three bottlenecks are unlikely to be overcome by carrier redesign alone.

Start with carrier structure optimization: it is feasible to attach specific targeting ligands to a nanoparticle surface in such a way as to make drug delivery active, thereby increasing tumor penetration by nanoparticles and reducing non-specific organ drug retention. Second, innovation of carrier materials: natural or polymeric substances of low price and total biodegradability merit use for this purpose — they help to cut industrial production costs and reduced clinical medication use. Third, co delivery combination strategies: paclitaxel may be co encapsulated—along with neuroprotective or myeloprotective substances—in a single nanocarrier, so as to treat simultaneously both hematological and neurological toxicity (as a whole) caused by standard chemotherapy. Fourth, promotion of clinical transformation: there is an urgent need for large-scale, multi center trials involving polymeric micelles of paclitaxel to help bring about clinical success with newer targeted nano formulations of this drug.

References

- [1] El-Aidy, N., & El-Sayed, R. A. (2023). Paclitaxel molecular mechanism of anticancer action and intrinsic cytotoxic risk in rapidly dividing somatic cells. *Frontiers in Pharmacology*, 14, 1157306.
- [2] Srivastava, A., & Sharma, S. (2023). Cremophor-EL-associated hypersensitivity and toxicities of conventional paclitaxel: Updated clinical perspectives. *Journal of Pharmacy and Pharmacology*, 75(11), 901–914.
- [3] Zhang, L., & Yang, J. X. (2019). Research progress on pharmacological effects and formulation-related toxicity of paclitaxel. *Chinese Journal of Pharmacology*, 35(8), 1065–1070.
- [4] Klein, I., Lehmann, H. C., Wiesen, M. H. J., Albert, V., & Bobylev, I. (2021). Pathomechanisms of paclitaxel-induced peripheral neuropathy. *Toxics*, 9(10), 229.
- [5] Ilinskaya, A. N., Clogston, J. D., McNeil, S. E., & Dobrovolskaia, M. A. (2015). Induction of oxidative stress by Taxol vehicle Cremophor-EL triggers production of interleukin-8 by peripheral blood mononuclear cells through the mechanism not requiring de novo synthesis of mRNA. *Nanomedicine: Nanotechnology, Biology and Medicine*, 11(8), 1925–1938.
- [6] Choudhury, A., & Roy, S. (2024). Hypersensitivity reactions to solvent-based paclitaxel in contemporary oncology practice: A multi-institutional retrospective analysis. *Supportive Care in Cancer*, 32(5), 2341–2349.
- [7] Shinde, V. R., & Rengan, A. K. (2022). Altered tissue biodistribution of paclitaxel induced by Cremophor-EL micelles: Revisiting preclinical observations in modern nanomedicine context. *Photodiagnosis and Photodynamic Therapy*, 39, 102915.
- [8] Bernhard, W., Barreto, K., Toledo, D., El-Sayed, A., Jett, K. A., Casaco, A., Fonge, H., & Geyer, C. R. (2023). Evaluation of nimotuzumab Fab2 as an optical imaging agent in EGFR-positive cancers. *Scientific Reports*, 13(1), 10990.
- [9] Hertz, D. L. (2024). Nonlinear pharmacokinetics of Cremophor-solubilized paclitaxel: Clinical implications for dose-limiting toxicities. *European Journal of Cancer*, 202, 114024.
- [10] Gradishar, W. J., Tjulandin, S., & Davidson, N. (2005). Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. *Journal of Clinical Oncology*, 23(31), 7794–7803.
- [11] Pei, Q., Jiang, B. W., Hao, D., & Li, Y. (2023). Albumin-bound paclitaxel: Updated understanding of gp60-SPARC-mediated tumor accumulation in preclinical and clinical settings. *Acta Pharmaceutica Sinica B*, 13(8), 3252–3276.

- [12] Li, Y., & Zhang, H. (2024). Liposomal paclitaxel delivery: Advances, limitations and clinical translation update. *Advanced Drug Delivery Reviews*, 204, 115728.
- [13] Liu, Y., & Hu, Q. H. (2022). Preparation, toxicity reduction mechanism and clinical research progress of liposomal paclitaxel. *Chinese Journal of New Drugs*, 31(11), 1089–1096.
- [14] Zhang, L., Chan, J. M., & Wang, A. Z. (2020). Polymeric nanoparticle paclitaxel delivery systems for cancer therapy: A review. *ACS Omega*, 5(36), 23046–23060.
- [15] Chen, B., Gong, L., Feng, J., Song, M., Jin, M., Chen, L., Gao, Z., & Huang, W. (2025). Improving the treatment of brain gliomas through small-particle-size paclitaxel-loaded micelles with a high safety profile. *Pharmaceutics*, 17(8), 965.
- [16] Pandey, M., Patel, A., & Shah, S. (2022). Adverse event profile for nanoparticle albumin-bound paclitaxel compared with solvent-based taxanes in solid-organ tumors: A systematic review and meta-analysis of randomized clinical trials. *Frontiers in Pharmacology*, 13, 923785.
- [17] Xu, Y., Li, H., & Wu, Y. (2024). Comparative safety and efficacy of three paclitaxel formulations for advanced non-small cell lung cancer: A retrospective cohort study. *BMC Cancer*, 24(1), 892.
- [18] Patel, M., & Mehta, K. (2025). Manufacturing bottlenecks and health-economic barriers for clinical-grade nanopaclitaxel formulations. *Journal of Pharmaceutical Innovation*, 20(2), 387–401.
- [19] Hershman, D. L., Till, C., & Wright, J. D. (2023). Persistent peripheral neuropathy following nab-paclitaxel and liposomal paclitaxel therapy. *Journal of the National Cancer Institute*, 115(5), 612–621.
- [20] Anastácio, W. L. D. N., Dos Santos, T. M., Souto, F. O., & Acevedo, E. O. (2026). Mechanism-based management of taxane-induced neuropathic pain in breast cancer survivors: A critical review. *Frontiers in Pain Research*, 7, 1717395.
- [21] Mitchell, M. J., & Jain, R. K. (2024). Unmet challenges in paclitaxel nanoformulations: Cost, residual toxicities, and poor target specificity. *Nature Reviews Clinical Oncology*, 21(8), 489–506.